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MSG to laboratory animals can produce
delayed, but permanent defects in hormone
secretion and drug metabolism, contributing to
long-term, serious health consequences.
Another of their studies found that prenatal
administration of either one of the two sub-
stances can result in a multitude of long-term
reproductive, growth, hepatic and neural dys-
functions. One finding, in particular, is disturb-
ing: neonatal administration of phenobarbital
can induce a delayed but permanent elevation
in the activities of several hepatic drug metabo-
lizing enzymes. These enzymes break down
specific substances, when their activities are
elevated, these drugs are broken down faster.
One would expect such elevated activity right
after administration of phenobarbital, but not
much later. However, it appears that at sexual
maturity, when gender dependent differences
in drug metabolism appear, the hepatic drug
metabolizing enzymes are induced again and
remain overexpressed for the rest of life. In rats
exposed as neonates to phenobarbital this
results in a shorter lifespan, and a great increase
in tumor formation.
Neonatal exposure to MSG has a different
effect on growth hormone production. It caus-
es a permanent reduction in the secretion of
growth hormone which leads to a reduced pro-
duction of the drug-metabolizing enzymes.
This hampers the metabolization of drugs and
toxic substance. The reduced quantity of
growth hormone leads to stunted growth and
irreversible obesity. Like phenobarbital, defects
resulting from neonatal exposure to MSG are
not apparent until adulthood.
Dr. Shapiro and his group are currently
working to answer these questions: How do the
chemicals induce the defects? How are the
defects expressed? The group has observed
that, when the production of growth hormone
is disturbed, the level of drug metabolizing
enzymes is affected. They found that in male
and female rats, prenatally exposed to pheno-
barbital, there were permanent defects in the
expression of these enzymes. The mechanism
by which the abnormal profile of growth  hor-
mone disrupts the enzyme expression is not
known, and the group proposes to investigate
it.
It is known that men, exposed perinatally to
phenobarbital, have a considerable higher inci-
dence of delayed puberty, undescended testes,
and genital abnormalities. In women this expo-
sure leads to irregular menstrual cycles and
problems during pregnancy. Both sexes score
lower on IQ tests as adults. Further, phenobar-
bital is a known carcinogen that induces the
overexpression of selected hepatic enzymes that
can increase the metabolism of innocuous
compounds into carcinogenic and toxic
metabolites. Perinatal exposure to the barbitu-
rate has been reported to subsequently increase
the risk of cancer in adult rats and children.
Phenobarbital and MSG are just two sub-
stances that can have an impact on drug
metabolism. There are many other compounds
that are in drugs or food and their impact on
human metabolism is unknown. One of these,
aspartame, is used widely as a sweetener. “Our
studies with rats have shown that the sweeten-
er, containing an amino acid like MSG, could
produce subtle developmental defects in
growth hormone secretion,” explains Dr.
Shapiro. “It is estimated that children consume
almost 100 mg of aspartame per kg of body
weight per day, a level approaching the adverse
doses found in animal studies. Children under
the age of five are particularly vulnerable, their
hepatic and neuroendocrine differentiation are
still incomplete and early constant exposure to
low levels of food additives could permanently
alter hormone secretion, the expression of
hepatic drug metabolizing enzymes and/or
their responses to inducing agents. Such effects
could unknowingly affect the efficacy of drug
therapy or the susceptibility to chemically-
induced cancers in adulthood.”
Sports Medicine Symposium for Equine Practitioners
Saturday,March 22 and Sunday,March 23,2003
Registration/participation fee: $175 Saturday only; $200 Saturday plus Sunday wet labs.
March 22:Lecture Topics
Performance problems in the Race Horse—Dr. Ben Martin
Performance problems in the Sport Horse—Dr. Elizabeth Davidson
Cardiovascular Problems in the Equine Athlete—Dr. Virginia Reef
Obscure Lameness Problems in the Equine Athlete—Dr. Mike Ross
Exercise Physiology: What You Need to Know—Dr. Ric Birks
Evaluation of Cardiac Output and Myocardial Function in Exercising Horses—Dr. Mary
Durando
Muscular Problems associated with Poor Performance—Dr. Jill Beech
Motion Correction for Standing Equine MRI—Dr. Lexi Lawrence
Suspensory desmitis and its response to treatment with high energy extracorporeal shock wave
therapy—Dr. Olga Seco
Where we stand and where we are moving toward with respiratory surgery—Dr. Eric Parente
All presenters with exception of Dr. Mary Durando are New Bolton Center faculty/clinicians
March 23:Wet Labs 
Station A - High speed treadmill demonstration
Station B - Endoscopic evaluation of upper airway dysfunction detected at speed
Case discussions at 2 stations - half of participants in each group
Station C - Lameness videos
Station D - Scintigraphic case evaluations
CE credits: 8 hours
Registration limited to 80 for Saturday sessions, 60 (max.) for Sunday wet labs
Saturday Sessions will be held in Woerner Amphitheatre, George D. Widener Hospital for
Large Animals, New Bolton Center, Kennett Square, Pa.
Wet Labs to be held in the new Scott Equine Sports Medicine Building, Jeffords Treadmill
Building, Scintigraphy station, New Bolton Center.
Please contact Office of Development, New Bolton Center, for detailed information and regis-
tration forms. Tel: 610-444-5800. ext. 2500 or email Patricia Hall at <phall@vet.upenn.edu>
